ER Positive: 248 Real Stories

248 stories match ER positive. 216 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male Breast Cancer Controlled for Years Through Multiple Lines of Targeted and Endocrine Therapy

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: Initial tumor ER-positive, PR-positive, HER2-positive; later ER-positive, PR-negative, HER2-negative; PIK3CA mutation; germline BRCA1/2 negative

Metastatic Site: bones, pleura, liver

After a 5-year and 6-month disease-free interval, the cancer recurred in bone and later progressed to the pleura and liver. He died in January 2021, more than 13 years after his 2007 breast-cancer diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Breast Tumor Disappears on Imaging During Treatment for Multiple Myeloma

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive, PR-positive, HER2-negative

The breast lesion showed a complete radiologic response before planned surgery, and there was no evidence of breast-cancer relapse or progression through 2022, about 5 years after diagnosis.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Recurs After a 19-Year Remission and Responds to Later Chemotherapy

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Initial tumor: PR-positive, ER-negative, HER2-negative. Recurrence: ER-positive, PR-negative

Metastatic Site: bones

The cancer recurred after a 19-year remission and later spread to bone. More than 21 years after the original diagnosis, she had marked tumor shrinkage, was in good general condition, and had 10 months of progression-free survival after utidelone plus capecitabine.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male breast cancer in both breasts linked to Klinefelter syndrome, initially missed

Patient Info: Anonymized, Male | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Klinefelter syndrome

Metastatic Site: spine / bone

With advanced metastatic disease and an estimated prognosis of weeks or less, care focused on symptom relief under the palliative-care team.

PubMed Central
OutcomeEnd of Life / Hospice
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III Breast Cancer Linked to Paraneoplastic Neuromyelitis Optica

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: ER-positive, PR-positive, HER2-negative; tumor AQP4 expression

A 51-year-old woman with Stage III hormone-receptor-positive breast cancer developed a rare paraneoplastic neurologic disorder that caused severe vomiting and spinal-cord symptoms.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic Breast Cancer Treatment Complicated by a Supplement–Drug Interaction

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-negative

Metastatic Site: bones

She resumed ribociclib with letrozole after the supplement was discontinued and the treatment-related neutropenia improved enough to restart therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Breast tumor with extensive tissue death (infarction)

Patient Info: Anonymized, Female

Biomarkers: Oestrogen receptor-positive; HER2 equivocal; confirmatory HER2 FISH was not performed

After 1.5 years of endocrine therapy, there was no clinical evidence of residual tumour.

PubMed Central
OutcomeResponding Well
Susan, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Susan's Survivor Story

Patient Info: Susan, Female, 70+

Biomarkers: 2021 breast cancer described as estrogen-positive and progesterone-positive; HER2 not reported. First breast cancer biomarker status not reported.

As of August 2023, Susan was living in survivorship after a first breast cancer treated with lumpectomy, chemotherapy, and radiation and a later separate breast cancer treated with bilateral mastectomy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Breast AdenocarcinomaBreast Cancer

Occult Metastatic Breast Cancer First Appears as a Sternal Mass

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-negative; BRCA1/2 testing negative

Metastatic Site: sternum

More than 3 years after the sternal mass was first detected, imaging showed no active breast or chest-wall disease and the cancers were described as appearing in remission while she continued tamoxifen.

PubMed Central
OutcomeResponding Well
Megan, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic breast cancer with a blood condition that mimicked multiple myeloma

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive

Metastatic Site: bone

Her pain came under control and the metastatic breast cancer remained stable for approximately 5 years. MGUS did not progress to myeloma, and she later died from causes unrelated to cancer.

PubMed Central
OutcomeIn Memory
Sarah, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HR-Positive Breast Cancer: Sarah's Survivor Story

Patient Info: Sarah McDonald, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

Sarah was 10 years from diagnosis without a recurrence and described the breast cancer as successfully treated. She later paused hormone therapy, completed IVF and gave birth at age 48.

The Patient Story
OutcomeCancer-Free / Long-Term Survivor
Christine, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Elliott, Female, Under 40 | Stage III

Biomarkers: Estrogen receptor-positive; HER2 and progesterone receptor status not reported

As of May 2023, Christine was about 3 years from diagnosis and in survivorship after chemotherapy, lumpectomy, and radiation. She reported lasting physical and emotional effects but did not state a formal NED status.

YouTube — The Patient Story
OutcomeSurvivorship / Completed Treatment
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Chemotherapy complication: methotrexate absorbed into the bloodstream after spinal injection

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Oncotype DX Recurrence Score 20

Metastatic Site: leptomeninges / central nervous system; brain

Five months after leptomeningeal carcinomatosis was recognised, she developed a new 2 cm brain lesion and neurological decline. Her family chose supportive care, and she died 10 days after transfer to inpatient hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer that spread to the thymus gland

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive; progesterone receptor-positive; HER2-negative

Metastatic Site: thymus

She had a good response after 4 cycles of abemaciclib, anastrozole and goserelin and continued endocrine treatment with surveillance of the opposite breast.

PubMed Central
OutcomeResponding Well
Becki, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Becki's Patient Story

Patient Info: Becki, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of 2023, Becki was receiving ongoing treatment for Stage II triple-positive breast cancer after recently completing mastectomy and experiencing chemotherapy-related fatigue, hair loss, and chemo fog.

Our Cancer Stories
OutcomeCare Ongoing